Abstract
Background: Potassium bromide is used as a sedative and an anti-epileptic drug for children and adolescents. Rodent animal studies have shown that bromide ions inhibit thyroid hormone synthesis by decreasing the iodine concentration in thyroid tissue. Aim: To observe the short-term clinical effects of combined treatment with potassium bromide and methimazole in patients with Graves’ disease. Materials and methods: Sixty patients with Graves’ diseases were randomized in groups. Thirty patients in the combined treatment group were treated with methimazole (10 mg, tid) and potassium bromide (1 g, tid); 30 patients in the methimazole only group were treated with methimazole (10 mg, tid) and starch placebo (1 g, tid). All the patients were treated with metoprolol tartrate (25 mg, bid) to control the symptoms and signs of hyperthyroidism. Patients were treated for one month. Clinical symptoms and potential side effects were monitored. Serum thyroid hormone levels were measured before and after the treatments. Results: Clinical hyperthyroidism symptoms were improved in both groups, with or without potassium bromide. Patients in the combined treatment group displayed improved clinical hyperthyroidism symptoms 10 days earlier on average (p<0.05). Furthermore, blood thyroid hormone levels decreased to normal levels in 93% (28/30) of patients in the combined treatment group, compared with only 37% (5/30) of patients in the methimazole only group (p<0.05). Conclusions: Treatment of patients with Graves’ disease with a novel combination therapy consisting of potassium bromide and methimazole resulted in a rapid improvement in clinical symptoms and decreased blood thyroid hormone levels to homeostatic levels faster than methimazole treatment alone.
Similar content being viewed by others
References
Singer PA, Cooper DS, Levy EG, et al. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association. JAMA 1995, 273: 808–12.
Abraham-Nordling M, Byström K, Törring O, et al. Incidence of Hyperthyroidism in Sweden. Eur J Endocrinol 2011, 165: 899–905.
Burch HB, Wartofsky L. Graves’ ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev 1993, 14: 747–93.
Schwartz KM, Fatourechi V, Ahmed DD, Pond GR. Dermopathy of Graves’ disease (pretibial myxedema): long-term outcome. J Clin Endocrinol Metab 2002, 87: 438–46.
Surks MI, Chopra IJ, Mariash CN, Nicoloff JT, Solomon DH. American Thyroid Association guidelines for use of laboratory tests in thyroid disorders. JAMA 1990, 263: 1529–32.
Patwardhan NA, Moroni M, Rao S, Rossi S, Braverman LE. Surgery still has a role in Graves’ hyperthyroidism. Surgery 1993, 94: 1108–12.
Cooper DS. Antithyroid drugs. N Engl J Med 1984, 39: 1353–62.
Korinthenberg R, Burkart P, Woelfle C, Moenting JS, Ernst JP. Pharmacology, efficacy, and tolerability of potassium bromide in childhood epilepsy. J Child Neurol 2007, 22: 414–8.
Pavelka S. Metabolism of bromide and its interference with the metabolism of iodine. Physiol Res 2004, 53(Suppl 1): S81–90.
Zung WW. A rating instrument for anxiety disorders. Psychosomatics 1971, 12: 371–9.
Oguni H, Hayashi K, Oguni M, et al. Treatment of severe myoclonic epilepsy in infants with bromide and its borderline variant. Epilepsia 1994, 35: 940–5.
Homsanit M, Sriussadaporn S, Vannasaeng S, Peerapatdit T, Nitiyanant W, Vichayanrat A. Efficacy of single daily dosage of methimazole vs. propylthiouracil in the induction of euthyroidism. Clin Endocrinol (Oxf) 2001, 54: 385–90.
Kampman JP, Hansen JM. Clinical pharmacokinetics of antithyroid drugs. Clin Pharmacokin 1981, 6: 401–28.
Mashio Y, Beniko M, Ikota A, Mizumoto H, Kunita H. Treatment of hyperthyroidism wih a small single daily dose of methimazol. Acta Endocrinol (Copenh) 1988, 99: 139–44.
Brodie MJ. Antiepileptic drug therapy the story so far. Siezure 2010, 19: 650–5.
Velický J, Titlbach M, Dusková J, Vobecký M, Strbák V, Raska I. Potassium bromide and the thyroid gland of the rat: morphology and immunohistochemistry, RIA and INAA analysis. Ann Anat 1997, 179: 421–31.
Author information
Authors and Affiliations
Corresponding author
Additional information
D.L., H.P., and X. Li contributed equally to this manuscript.
Rights and permissions
About this article
Cite this article
Li, D., Pei, H., Li, X. et al. Short-term effects of combined treatment with potassium bromide and methimazole in patients with Graves’ disease. J Endocrinol Invest 35, 971–974 (2012). https://doi.org/10.3275/8188
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.3275/8188